A Potential Drug Target or Biomarker for CNOT7: The Brain-Tumor Suppressor

Target Name: CNOT7

NCBI ID: G29883

CNOT7

A Potential Drug Target or Biomarker for CNOT7: The Brain-Tumor Suppressor

Abstract:

CNOT7 (BTG1-binding factor 1) is a non-coding RNA molecule that has been found to be highly expressed in various human tissues, including brain. Its potential functions as a drug target or biomarker are being explored due to its unique expression patterns and its involvement in various cellular processes. In this article, we will discuss the current understanding of CNOT7, its potential drug target properties, and its role as a biomarker for brain tumors.

Introduction:

CNOT7 is a non-coding RNA molecule that is 1,252 nucleotides long and has a calculated molecular weight of 41.9 kDa. It is expressed in various human tissues, including brain, heart, liver, and kidney. The function of CNOT7 is not well understood, but it is involved in various cellular processes, such as cell growth, apoptosis, and transcriptional regulation.

Potential Drug Target or Biomarker:

Several studies have suggested that CNOT7 may have potential as a drug target or biomarker. Its unique expression patterns in various human tissues, including brain, make it an attractive target for researchers. The expression of CNOT7 has been shown to be regulated by various factors, such as microRNA (miRNA) and long non-coding RNA (lncRNA).

One of the most promising aspects of CNOT7 as a drug target is its role in cell signaling pathways. Studies have shown that CNOT7 has been shown to be involved in various signaling pathways, including the PI3K/Akt signaling pathway (4), the TGF-灏? signaling pathway (5), and the Wnt signaling pathway. These signaling pathways are involved in various cellular processes, including cell growth, apoptosis, and angiogenesis. Therefore, targeting these pathways may lead to new therapeutic options for various diseases.

Another potential aspect of CNOT7 as a drug target is its role in cancer progression. Several studies have shown that CNOT7 is involved in the progression of various types of cancer, including breast, ovarian, and colorectal cancer (8, 9). Therefore, targeting CNOT7 may be a promising strategy for the development of new cancer therapies.

In addition to its potential as a drug target, CNOT7 has also been suggested as a potential biomarker for brain tumors. The expression of CNOT7 has been shown to be elevated in various types of brain tumors, including glioblastoma. Therefore, using CNOT7 as a biomarker for brain tumors may be a promising strategy for the early detection and diagnosis of these aggressive types of tumors.

Conclusion:

CNOT7 is a non-coding RNA molecule that has been found to be expressed in various human tissues, including the brain. Its unique expression patterns and involvement in various cellular processes make it an attractive target for researchers. The potential functions of CNOT7 as a drug target or biomarker are being explored due to its involvement in various cellular signaling pathways and its involvement in cancer progression. Further studies are needed to fully understand the role of CNOT7 in these processes and its potential as a drug target or biomarker.

Protein Name: CCR4-NOT Transcription Complex Subunit 7

Functions: Has 3'-5' poly(A) exoribonuclease activity for synthetic poly(A) RNA substrate (PubMed:20634287, PubMed:31439799, PubMed:19276069). Its function seems to be partially redundant with that of CNOT8 (PubMed:19605561). Catalytic component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation (PubMed:20634287, PubMed:31439799, PubMed:19276069). During miRNA-mediated repression the complex seems also to act as translational repressor during translational initiation (PubMed:20065043). Additional complex functions may be a consequence of its influence on mRNA expression (PubMed:23236473, PubMed:19276069). Associates with members of the BTG family such as TOB1 and BTG2 and is required for their anti-proliferative activity (PubMed:23236473, PubMed:19276069)

The "CNOT7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNOT7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets